Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Chemring's Roke wins 'strategically important' MoD missile defence contract

(Sharecast News) - Chemring said on Wednesday that its Roke business has won a "strategically important" UK Ministry of Defence missile defence contract valued at £251m over six years. The framework contract, known as Science & Technology Oriented Research & development in Missile defence (STORM), encompasses a broad spectrum of missile defence activities and capabilities.

"Partnering with the UK Missile Defence Centre (UK MDC) Roke will lead a UK sovereign industry collaborative effort to provide security to the UK, and its allies, by countering current and future threats, including ballistic and hypersonic missiles," Chemring said.

Commencing immediately, the STORM framework will see Roke "enhance its role as a trusted partner to the UK MDC at the heart of the UK missile defence ecosystem at what is a pivotal moment for national defence and security".

Roke, the overall prime contractor, will self-deliver elements of the contract and will also manage industry partners as they deliver the significant majority of contract value.

Chief executive Michael Ord said: "We are delighted that Roke has been trusted to deliver STORM for the UK MDC. In today's complex and changing security environment effective missile defence is crucial to protecting the UK's interests.

"This contract recognises Roke's heritage in helping customers solve complex problems, and places Roke at the heart of the UK's missile defence research and development activities."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.